Arkolith/Insider Trading/OTLC/Form 4

Trieu Vuong

CHAIRMAN AND CEO, Director, 10% OwnerOncotelic Therapeutics, Inc. (OTLC) · full profile →Form 4 · filed Jan 31, 2025
Net Buying
Open-Market Buys
$10K
Open-Market Sells
$0
Net Open-Market Flow
$10K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 31, 2025Buy(P)64K$0.03$2K93.2M
Jan 30, 2025Buy(P)100K$0.03$3K93.1M
Jan 29, 2025Buy(P)183K$0.03$5K93.0M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-25-004486) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML